More than 150 hospitals have sued the U.S. Department of Health and Human Services (HHS) in the latest attempt by providers to end steep cuts in 340B reimbursement at their off-campus outpatient sites.
Filed in district court in Washington, D.C.,
…
Category: Federal
Drug manufacturer Pfizer last week cited a federal judge’s June 16 opinion in AstraZeneca’s 340B contract pharmacy lawsuit in Pfizer’s own lawsuit aimed at striking down federal restrictions on manufacturer copay assistance to Medicare beneficiaries.
Pfizer sued the U.S. Health
…
The U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) posted a notice yesterday about changes to the covered entity registration and manufacturer pricing components of 340B OPAIS, the 340B program database.
Today is the first day
…
On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it asked them to provide updates by June 1 on their plans to comply with the law.
At least three of
…
Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal filings in
…
The U.S. Centers for Medicare & Medicaid Services (CMS) announced on Monday that Massachusetts’ Medicaid director Daniel Tsai has been named Deputy Administrator of CMS and Director of CMS’s Center for Medicaid and CHIP Services (CMCS). A record 80 million
…
Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.
This normally might be a
…
U.S. Health and Human Services (HHS) Secretary Xavier Becerra this morning announced his six appointees to the long-awaited 340B administrative dispute resolution (ADR) board.
The move will be welcomed by the 340B provider community, which has pushed for the creation
…
Hospitals, health centers, and clinics are losing a projected $3.2 billion a year in 340B program savings due to six drug manufacturers’ denials of 340B pricing on drugs shipped to contract pharmacies, the federal government said in a court filing
…
Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling last week that the government had no basis for stating in December that the 340B statute unambiguously requires manufacturers to
…